Week 11: Parkinson’s Disease – Early Signs, Brain Changes & Treatment:

Quick links

Recording:

If you missed the class or need to hear it again (lots of information on our upcoming semester), view the recording here!

Additional Resources

Introduction

(Dorsey et al., 2018), (Postuma et al., 2015)

Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting nearly 10 million people worldwide. While the condition is often associated with motor symptoms such as tremor, rigidity, and slowness of movement, the earliest signs of PD frequently appear years before these hallmark features. These subtle changes, which may include alterations in mood, sleep, sense of smell, or fine motor control, are sometimes mistaken for normal aging. Recognizing these early indicators is critical for timely diagnosis, effective management, and maintaining quality of life.

This paper provides a comprehensive exploration of PD, organized into four sections. Section I focuses on early signs and subtle symptoms, emphasizing both motor and non-motor indicators that can signal the disease’s onset. Section II examines brain changes and pathophysiology, including dopaminergic neuron loss, alpha-synuclein pathology, and multisystem involvement. Section III reviews medical treatments and therapies, including pharmacologic approaches, surgical options and experimental interventions. Section IV highlights lifestyle strategies, cognitive training, research advances, and integrative approaches that promote brain fitness and enhance quality of life. Together, these sections offer a foundation for understanding PD and empowering older adults to take an active role in preserving brain health.

Parkinson’s disease (PD) impacts people in different ways. Not everyone will experience all the symptoms of Parkinson’s, and if they do, they won’t necessarily experience them in quite the same order or at the same intensity. There are typical patterns of progression in Parkinson’s disease that are defined in stages. Joseph Jankovic, MD discusses those patterns in terms of the forms and stags of Parkinson's disease.

Glossary of Terms and Abbreviations

PD (Parkinson’s Disease): A progressive neurodegenerative disorder affecting movement and multiple neurotransmitter systems.
DBS (Deep Brain Stimulation): A surgical therapy involving implanted electrodes to modulate abnormal brain activity.
BDNF (Brain-Derived Neurotrophic Factor): A protein that supports neuron survival, growth, and plasticity.
RBD (REM Sleep Behavior Disorder): A sleep disorder where individuals physically act out dreams due to lack of normal muscle paralysis.
L-DOPA (Levodopa): A dopamine precursor used to treat PD motor symptoms.
MAO-B inhibitors: Drugs that inhibit monoamine oxidase B, an enzyme that breaks down dopamine.
COMT inhibitors: Medications that block catechol-O-methyltransferase, prolonging levodopa’s effect.
Nigrostriatal pathway: Dopamine pathway connecting the substantia nigra to the striatum, crucial for movement regulation.
Lewy bodies: Abnormal protein aggregates (alpha-synuclein) found in PD neurons.

Want to learn more about Parkinson’s disease and how it affects the brain and body? Watch this short 8-minute Khan Academy video for a clear and insightful overview.

Section I: Early Signs and Subtle Symptoms of Parkinson’s Disease

(Postuma et al., 2015), (Berendse & Ponsen, 2006), (Schenck et al., 2013), (Lebouvier et al., 2009; Goldstein et al., 2011; Leentjens et al., 2003), (Jankovic, 2008; Schenk et al., 2017), (DeLong & Wichmann, 2007), (Kordower et al., 2013), (Kehagia et al., 2010), (Maillet et al., 2016), (Elbaz et al., 2016), (Klein & Westenberger, 2012), (Gatto et al., 2014)

1. Prodromal Phase and Non-Motor Symptoms

The prodromal phase of PD can precede a formal diagnosis by a decade or more. Non-motor symptoms often provide the first clues. Loss of smell (hyposmia) is common, affecting up to 90% of individuals years before motor onset, making olfactory testing an area of interest for early screening.

Sleep disturbances, particularly rapid eye movement (REM) sleep behavior disorder (RBD), are another early indicator. Individuals with RBD act out dreams due to the loss of normal muscle paralysis during REM slaeep. Longitudinal studies indicate that 30–80% of people with idiopathic RBD eventually develop PD or related disorders.

Other early non-motor symptoms include constipation, fatigue, autonomic dysfunction such as low blood pressure when standing, and mood changes including anxiety or depression. These subtle physiological and emotional shifts highlight the importance of awareness in older adults and community education programs.

This chart illustrates the progression of Parkinson’s disease (PD) across the lifespan. It shows how early, subtle “prodromal” signs—such as sleep disturbances, loss of smell, constipation, and mild cognitive or mood changes—can appear years before a clinical diagnosis. Over time, as more nerve cells are affected, motor symptoms like tremor, stiffness, and slow movement emerge. The diagram contrasts the typical healthy aging path with the Parkinson’s trajectory, highlighting that early detection and intervention during midlife may have a beneficial impact on slowing disease progression.

2. Early Motor Changes

Subtle motor signs often follow or accompany non-motor symptoms. These include a slight tremor in one hand, reduced arm swing while walking, slowed fine motor tasks such as writing or buttoning clothes, and micrographic (small handwriting).

Bradykinesia, or slowness of movement, may first appear as decreased facial expressiveness (hypomimia) or reduced spontaneous movement. Some individuals notice difficulty turning in bed, dragging a foot, or mild imbalance. These early motor changes are typically asymmetrical and arise from progressive dysfunction in the nigrostriatal dopamine pathway. By the time overt motor symptoms appear, approximately 60–80% of dopaminergic neurons in the substantia nigra have degenerated (Kordower et al., 2013).

This image illustrates the five stages of Parkinson’s disease progression, based on the Hoehn and Yahr (HY) scale:

Stage 0: No visible symptoms.
Stage 1–2 (Early stage, HY 0–2.5): Mild symptoms like slight tremors or stiffness, often affecting one side of the body.
Stage 3–4 (Complicated stage, HY 3–4): Balance problems, slower movements, and greater difficulty with walking and coordination.
Stage 5 (Late stage, HY 5): Severe disability—patients may require a wheelchair or full assistance with daily activities.

This table shows the motor and non-motor symptoms of Parkinson’s disease (PD), grouped by when they typically appear:

Pre-Motor Symptoms: These often occur before movement problems begin, including loss of smell, constipation, sleep disorders, mood changes, and low blood pressure when standing (orthostatic hypotension).
Primary Motor Symptoms: The main movement-related signs of PD — tremor, slowness of movement (bradykinesia), muscle rigidity, and postural instability.
Secondary Motor Symptoms: Additional movement issues such as freezing of gait, small handwriting (micrographia), reduced facial expression, and uncontrolled or festinating walking.

Together, these categories illustrate how Parkinson’s affects both motor control and non-motor body systems, often years before diagnosis.

3. Cognitive and Emotional Manifestations

Cognitive changes, especially in executive function, may emerge early. Patients often report mental fatigue, trouble multitasking, or difficulty with planning. Emotional symptoms such as apathy, irritability, or mild depression can also appear before motor symptoms and reflect changes in dopamine, serotonin, and norepinephrine circuits.

Older adults may mistakenly attribute these changes to normal aging or life stress. Education programs can help participants understand that mood and movement are interconnected through shared neural pathways.

This image shows the neuropsychiatric symptoms often associated with Parkinson’s disease.
In addition to movement problems, many people experience emotional and cognitive changes such as:

Depression and anxiety
Apathy (loss of motivation)
Cognitive dysfunction and dementia
Psychosis (hallucinations or delusions)
Impulse control disorders
Confusion or delirium

These symptoms highlight that Parkinson’s affects both the mind and mood, not just movement.

4. Gender, Age, and Genetic Risk Factors

PD is more common in men than women, with a ratio of approximately 1.5 to 1. Age is the greatest risk factor; incidence rises sharply after 60, though about 10% of cases occur in individuals under 50, often linked to genetic mutations such as LRRK2 or PARK2. Environmental exposures, such as pesticides, rural living, or head trauma, may also increase risk. Awareness of these factors can help older adults understand their vulnerability and advocate for early screening.

5. The Importance of Early Recognition

Early recognition enables timely intervention, participation in clinical trials, and engagement in lifestyle strategies that support brain health. According to the Parkinson’s Foundation (2022), nearly 40% of patients report that initial symptoms were dismissed by healthcare providers. Community-based screening initiatives, such as smell tests, questionnaires about sleep or constipation, and observation of handwriting, can facilitate earlier referrals to specialists and improve long-term outcomes.

This image shows that Parkinson’s disease can cause speech impairments in three main areas: phonation (voice becomes soft or monotone), articulation (slurred or imprecise speech), and cognitive-linguistic function (difficulty organizing thoughts, reduced vocabulary, and grammatical errors).

Section II: Brain Changes and Pathophysiology of Parkinson’s Disease

(Kalia & Lang, 2015), (Kordower et al., 2013), (DeLong & Wichmann, 2007), (Obeso et al., 2008), (Spillantini et al., 1998), (Olanow & Brundin, 2013), (Braak et al., 2003), (Maillet et al., 2016), (Goldstein et al., 2011), (Kehagia et al., 2010), (Exner et al., 2012), (Tanner et al., 2011), (Langston et al., 1983), (Lebouvier et al., 2009), (Hirsch & Hunot, 2009), (Scheperjans et al., 2015), (Pal et al., 2022), (Carbon & Eidelberg, 2006), (Fisher et al., 2008),

Understanding the neurological underpinnings of Parkinson’s disease (PD) provides key insight into its symptoms, progression, and treatment targets. PD is primarily known as a movement disorder, but its roots lie deep within the intricate architecture of the brain, specifically in circuits governing motor control, emotion, motivation, and cognition. Modern research has revealed that PD is not a single disorder but rather a complex, multisystem disease that unfolds over years or even decades.

1. The Basal Ganglia and Dopaminergic Pathways

The most critical brain region affected in PD is the substantia nigra pars compacta, a small but powerful structure located in the midbrain. This area contains dopamine-producing neurons that project to the striatum (comprising the caudate nucleus and putamen), forming the nigrostriatal pathway, a circuit essential for smooth, coordinated movement. When approximately 60–80% of these neurons degenerate, the resulting dopamine deficit leads to the characteristic motor symptoms of PD, such as bradykinesia and rigidity.

The basal ganglia work as part of a broader network that includes the motor cortex, thalamus, and cerebellum. These structures communicate through complex feedback loops that fine-tune motor output. Dopamine acts as a modulator within this system, balancing excitatory and inhibitory signals. In PD, diminished dopamine disrupts this equilibrium, causing excessive inhibition of the thalamus and reduced activation of the motor cortex, essentially “slowing down” the body’s movement programs.

In this video, I discuss Parkinson's disease---the second most common neurodegenerative disease behind Alzheimer's disease. Parkinson's disease is associated with the degeneration and death of dopamine neurons in the substantia nigra.

The indirect pathway is a circuit in the basal ganglia best-known for its hypothesized role in the inhibition of movement. In this video, I discuss how the structures of the indirect pathway are thought to work together to suppress unwanted movements.

2. Lewy Bodies and Alpha-Synuclein Pathology

At the microscopic level, the defining neuropathological hallmark of PD is the presence of Lewy bodies, abnormal aggregates of the protein alpha-synuclein within neurons. Under normal conditions, alpha-synuclein contributes to synaptic vesicle function and neurotransmitter release. However, when it misfolds, it becomes toxic to neurons, disrupting cellular homeostasis and ultimately triggering apoptosis.

Postmortem studies have shown that alpha-synuclein pathology follows a predictable pattern described by Braak and colleagues (2003), beginning in the olfactory bulb and dorsal motor nucleus of the vagus nerve, regions involved in smell and autonomic control, before progressing to midbrain and cortical areas. This staging model helps explain why early symptoms like loss of smell, constipation, and sleep disturbances often precede motor decline. Later involvement of the limbic system and neocortex accounts for emotional and cognitive impairments in advanced stages.

This image shows how Parkinson’s disease develops when dopamine-producing neurons in the substantia nigradegenerate, forming Lewy bodies and triggering inflammation. This leads to motor symptoms (like tremors, stiffness, and slow movement) and non-motor symptoms (such as depression, anxiety, and fatigue).

This image compares a normal brain with one affected by Lewy body disease (LBD), a condition related to Parkinson’s.

In the LBD brain, there is widespread neuronal loss and accumulation of Lewy bodies—abnormal protein clumps made of alpha-synuclein—in key areas like the substantia nigra, hippocampus, cortex, and amygdala. These changes damage brain communication and lead to symptoms such as movement problems, memory loss, confusion, and mood changes.

3. Neurotransmitter Systems Beyond Dopamine

While dopamine loss is central to PD, it is not the only neurotransmitter affected. The serotonergic system, originating in the raphe nuclei, also degenerates and contributes to mood disorders, anxiety, and sleep dysfunction. The noradrenergic locus coeruleus is often involved early in PD, leading to fatigue, orthostatic hypotension, and impaired stress response. Additionally, cholinergic neurons within the nucleus basalis of Meynert degenerate, contributing to cognitive decline and dementia in later stages.

This multisystem involvement highlights PD’s heterogeneity, explaining why some individuals experience profound motor symptoms with minimal cognitive issues, while others face early executive dysfunction or apathy. For older adults learning about brain fitness, this complexity underscores that brain health depends on multiple, interacting neurotransmitter networks rather than any single chemical messenger.

4. Mitochondrial Dysfunction and Oxidative Stress

One of the most active areas of PD research focuses on mitochondrial dysfunction and oxidative stress. Dopaminergic neurons are particularly vulnerable because dopamine metabolism naturally produces reactive oxygen species (ROS). In PD, mitochondrial Complex I impairment amplifies oxidative damage, leading to cellular injury and death.

Environmental toxins, such as pesticides and heavy metals, can further inhibit mitochondrial enzymes, increasing the risk of PD development. This mechanism was first recognized in the 1980s when a synthetic drug contaminant, MPTP, was found to cause acute parkinsonism by selectively damaging nigral mitochondria. These findings provided a powerful model for studying neurodegeneration and testing new therapies.

This image shows how dopamine (DA) is produced and broken down in brain cells and how its deficiency contributes to Parkinson’s disease. Damage to mitochondria and oxidative stress cause dopamine-producing neurons to die, leading to motor symptoms. The imbalance in dopamine metabolism triggers cell death and further reduces dopamine levels in the brain.

5. Neuroinflammation and the Gut–Brain Axis

Recent discoveries have highlighted the role of neuroinflammation in PD progression. Microglia, the brain’s immune cells, become chronically activated in affected regions, releasing pro-inflammatory cytokines that exacerbate neuronal damage. This persistent immune activation may be driven not only by dying neurons but also by peripheral immune signals, linking PD to systemic inflammation and the gut microbiome.

Indeed, growing evidence supports the gut–brain hypothesis, which proposes that PD may originate in the gastrointestinal tract. Misfolded alpha-synuclein has been found in the enteric nervous system years before brain involvement, and studies show distinct differences in gut microbial composition among individuals with PD. Certain bacteria may promote inflammation or alpha-synuclein aggregation, whereas others appear protective. This emerging area of research has opened new possibilities for dietary and probiotic interventions aimed at slowing PD progression.

This image shows how Parkinson’s disease may begin in the gut and spread to the brain through inflammation and nerve pathways.

It illustrates a step-by-step process:

1️⃣ Inflammatory triggers in the gut cause intestinal inflammation and increased permeability.

2️⃣ This allows abnormal α-synuclein proteins to form and spread along the vagus nerve to the brain.

3️⃣ The process leads to systemic inflammation, neuroinflammation, and ultimately neurodegeneration—the loss of brain cells responsible for movement and coordination.

6. Brain Plasticity and Compensatory Mechanisms

Despite progressive neurodegeneration, the brain demonstrates remarkable plasticity, its ability to adapt and reorganize in response to damage. Functional imaging studies reveal that in early PD, undamaged brain regions can increase their activity to compensate for lost dopaminergic input. Exercise and cognitive stimulation may help strengthen these compensatory networks, supporting the rationale for lifestyle interventions in brain fitness programs.

For example, aerobic exercise has been shown to promote neurogenesis, enhance synaptic plasticity, and increase dopamine receptor availability. Such findings provide tangible hope for older adults, showing that while PD involves neuronal loss, it also engages the brain’s capacity for resilience and adaptation.

7. Toward a Systems View of Parkinson’s Disease

Today, PD is understood not merely as a “dopamine disease” but as a multi-system neurodegenerative disorder influenced by genetics, environment, metabolism, and inflammation. Advances in neuroimaging, genetics, and molecular biology continue to reveal how these factors interact across brain networks. For educators and learners focused on brain health, this system’s perspective underscores the importance of comprehensive approaches, encompassing medical, lifestyle, and psychosocial dimensions, in managing and potentially mitigating the effects of PD.

Section III: Medical Treatments and Therapies for Parkinson’s Disease

(Connolly & Lang, 2014), (Hauser, 2009), (Kvernmo et al., 2006), (Olanow et al., 2009), (Fox et al., 2018), (Schwab et al., 2013), (Richard et al., 2012), (Seppi et al., 2019), (Benabid et al., 2009), (Fasano et al., 2012), (Witt et al., 2013), (Elias et al., 2016), (APDA, 2025), (Marks et al., 2010), (Kikuchi et al., 2021), (Mortiboys et al., 2015), (Christine et al., 2019), (Pagano et al., 2022), (Cruise et al., 2011; Li et al., 2012), (Parkinson’s Foundation, 2022), (Fisher et al., 2008), (Ramig et al., 2001), (Espay et al., 2017), (Arora et al., 2015)

The management of Parkinson’s disease (PD) combines pharmacological, surgical, and rehabilitative approaches to alleviate symptoms, improve function, and maintain quality of life. While no cure currently exists, treatment innovations over the past several decades have dramatically improved outcomes and longevity for people with PD. Understanding how these therapies work, and the science behind them, provides essential insight for older adults interested in brain fitness and lifelong neuroprotection.

🎥 Watch this short video to learn about treatment options for Parkinson’s disease — including how medications help manage symptoms and improve quality of life.

1. Pharmacological Foundations: Levodopa and Dopaminergic Therapies

The gold standard of PD treatment remains levodopa (L-DOPA), a precursor of dopamine that crosses the blood–brain barrier. Once in the brain, levodopa is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase, replenishing the depleted neurotransmitter in the striatum. Because peripheral metabolism of levodopa can lead to side effects such as nausea and low blood pressure, it is administered with carbidopa or benserazide, which inhibits its conversion to dopamine outside the brain.

Levodopa’s efficacy in restoring movement remains unparalleled. However, long-term use can result in motor fluctuations, periods of “wearing off” or dyskinesias (involuntary movements). These complications arise from both disease progression and pulsatile dopamine stimulation. To address this, clinicians often employ dopamine agonists (e.g., pramipexole, ropinirole, rotigotine) that directly stimulate dopamine receptors and can smooth out fluctuations.

Additional agents such as MAO-B inhibitors (selegiline, rasagiline, safinamide) prevent dopamine breakdown, while COMT inhibitors (entacapone, opicapone) extend levodopa’s half-life. Combination therapy allows for individualized symptom management, minimizing side effects and optimizing control throughout the day.

Antiparkinson drugs are medications used to treat the symptoms of Parkinson's disease.

Most of these agents act by either increasing dopamine activity or reducing acetylcholine activity in the central nervous system. This pharmacology lecture covers topics such as pathophysiology of Parkinson's disease, striatum and substantia nigra, role of dopamine, GABA, and acetylcholine, MAO-B and COMT metabolism, mechanism of action and side effects of antiparkinson drugs. Drugs mentioned include; Levodopa, Carbidopa, Entacapone, Selegiline, Rasagiline, Bromocriptine, Ropinirole, Pramipexole, Rotigotine, Apomorphine, Benztropine, Biperiden, Procyclidine, Trihexyphenidyl, and Amantadine.

2. Non-Dopaminergic and Adjunctive Pharmacotherapies

As PD affects multiple neurotransmitter systems, treatments targeting other pathways can help manage non-motor symptoms. Anticholinergics such as trihexyphenidyl may reduce tremors in younger patients, though they are typically avoided in older adults due to cognitive side effects. Amantadine, originally an antiviral drug, provides modest benefit for dyskinesias through NMDA receptor antagonism and dopamine release.

For mood and sleep disturbances, antidepressants, melatonin, and selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed. Cholinesterase inhibitors like rivastigmine are used for Parkinson’s disease dementia, while modafinil or methylphenidate may help treat daytime fatigue. Managing these non-motor aspects is essential for preserving cognitive function and emotional well-being.

3. Surgical Treatments: Deep Brain Stimulation and Other Surgical Options

When medication becomes insufficient to control symptoms or causes intolerable side effects, surgical approaches such as deep brain stimulation (DBS) offer powerful alternatives. DBS involves implanting electrodes into specific brain regions, typically the subthalamic nucleus (STN) or globus pallidus internus (GPi), connected to a pulse generator that delivers continuous electrical impulses. These impulses modulate abnormal neuronal firing, reducing tremor, rigidity, and bradykinesia.

DBS has revolutionized PD treatment, offering improved motor control, reduced medication requirements, and enhanced quality of life. Candidates are typically individuals with advanced PD who still respond to levodopa but experience motor fluctuations or dyskinesia. The therapy requires multidisciplinary assessment and precise neurosurgical expertise. Importantly, DBS can also alleviate some non-motor symptoms such as sleep problems and mood disturbances.

Other surgical innovations include focused ultrasound and lesioning techniques such as pallidotomy and thalamotomy, modernized with MRI guidance for safety and accuracy. These procedures are typically considered for tremor-dominant cases or when DBS is not an option. As surgical and pharmacologic methods continue to evolve, a new wave of clinical research now seeks to move beyond symptom management toward modifying the underlying disease process.

Deep brain stimulation (DBS) can help reset faulty brain signals that cause symptoms of Parkinson’s disease, essential tremor, and epilepsy. In this procedure, also called neuromodulation, doctors implant a device that produces electrical impulses to disrupt irregular brain signals that cause involuntary movements. Stanford Health Care’s sophisticated technology and data-driven approach enable us to program your stimulator settings for optimal results.

Every year, approximately 60,000 people are diagnosed with Parkinson’s disease. In addition, about 10 million people in the United States have essential tremor—a neurological condition that causes a person's hands, head, or voice to shake. These conditions can seriously affect a person’s quality of life, preventing them from being able to dress or feed themselves or drive. At the same time, medications can have side effects and tend to lose effectiveness over time.

4. Current Clinical Trials in Parkinson’s Disease

Recent years have seen a rapid expansion of the Parkinson’s disease (PD) clinical trial landscape, with researchers focusing not only on improving symptom management but also on slowing disease progression. The American Parkinson Disease Association highlights multiple late-stage trials that target diverse mechanisms. For instance, ambroxol, a small molecule originally developed as a cough medicine, is now being tested in PD patients carrying GBA mutations to enhance glucocerebrosidase activity and improve lysosomal function. Similarly, prasinezumab, an antibody that binds misfolded α-synuclein, has advanced into Phase III studies after demonstrating potential to slow motor decline in earlier phases. Other agents, such as NLRP3 inflammasome inhibitors, are being evaluated for their ability to reduce neuroinflammation, another contributor to PD pathology.

These trials collectively reflect a shift in PD research toward disease-modifying approaches rather than purely symptomatic relief. As summarized by the Michael J. Fox Foundation (2025), investigational therapies increasingly aim to intervene in the biological processes driving neuronal loss—bridging the gap between symptomatic care and true neuroprotection.

"CBS Mornings" co-host Nate Burleson sits down with award-winning actor Michael J. Fox to talk about the latest developments in Parkinson's disease research and how he's managing the disease. Fox has a foundation that will be hosting an annual fundraiser this weekend in New York City.

In the third edition of The Michael J. Fox Foundation's whiteboard video series, Dr. Rachel Dolhun, movement disorder specialist and vice president of medical communications, breaks down the basics of Parkinson’s disease. To learn more about the Foundation and how you can help speed a cure, please visit: www.michaeljfox.org.

5. Experimental and Emerging Therapies for PD

Research into disease-modifying and restorative treatments for Parkinson’s disease (PD) has accelerated in recent years, with emphasis on targeting the underlying molecular and cellular mechanisms of neurodegeneration. Gene therapy represents one of the most promising approaches. Early-phase trials have explored adeno-associated virus type 2 (AAV2)–mediated delivery of genes such as glial cell line–derived neurotrophic factor (GDNF) to promote dopaminergic neuron survival and function. Although some studies have shown mixed clinical outcomes, neuroimaging evidence indicates enhanced dopamine uptake and improved neuronal integrity in targeted brain regions. The refinement of viral vectors, gene promoters, and delivery techniques continues to enhance safety and efficacy.

Parallel efforts in stem-cell and regenerative therapies aim to replace lost dopaminergic neurons and restore striatal dopamine transmission. Induced pluripotent stem cells (iPSCs) are being investigated as a renewable source of patient-specific dopaminergic progenitors. Preclinical and early human trials have demonstrated promising graft survival and integration, with reduced dyskinesias compared to fetal tissue transplants. The Michael J. Fox Foundation (2025) highlights stem-cell replacement, precision gene editing, and neuroprotective factor delivery as key innovation domains shaping PD’s future treatment landscape.

Beyond gene and cell-based therapies, several other experimental interventions target oxidative stress, inflammation, and metabolic dysfunction—key contributors to PD pathogenesis. Ursodeoxycholic acid (UDCA), a bile acid traditionally used to treat liver disease, has shown neuroprotective properties by stabilizing mitochondrial function and reducing oxidative damage in preclinical models. Phase II studies are underway to determine its potential as a disease-modifying therapy in humans.

A subset of gene therapies focus on restoring dopamine synthesis directly. For instance, adeno-associated viral vectors delivering aromatic L-amino acid decarboxylase (AADC) have shown improved motor performance and dopamine metabolism in patients with advanced PD. These findings suggest that targeted gene delivery may supplement or even partially replace pharmacologic dopamine therapy in the future.

Immunotherapy approaches are also under investigation to halt the progression of α-synuclein pathology. Monoclonal antibodies such as prasinezumab and cinpanemab have been designed to neutralize toxic α-synuclein aggregates and prevent their spread between neurons. Although early trials have not yet demonstrated significant clinical benefit, biomarker data indicate that such agents engage their intended targets and may slow disease-related neuronal injury.

Collectively, these emerging and experimental therapies—from neuroprotective compounds to gene and stem-cell–based interventions—reflect a decisive shift in PD research toward modifying and potentially reversing the disease process. While most remain in the investigational stage, they represent the most hopeful frontier in achieving long-term restoration of function and quality of life for individuals with Parkinson’s disease.

6. Rehabilitation and Neuroprotective Interventions

Beyond drugs and surgery, comprehensive PD care integrates physical, occupational, and speech therapy, each playing a critical role in maintaining mobility, communication, and independence. Exercise has emerged as one of the most effective non-pharmacologic interventions. Randomized controlled trials demonstrate that aerobic exercise, resistance training, and tai chi can improve motor performance, balance, and even cognitive function.

The Parkinson’s Outcomes Project, the largest-ever clinical study of PD, found that people who exercised regularly for at least 2.5 hours per week had a slower decline in quality of life compared to those who did not. Exercise promotes neuroplasticity, increases neurotrophic factors such as BDNF, and may even enhance dopamine receptor sensitivity. Encouraging consistent physical activity is thus central to both treatment and prevention of functional decline.

Speech therapy, particularly using the Lee Silverman Voice Treatment (LSVT LOUD) method, helps patients maintain clear speech and vocal strength. Occupational therapists guide adaptive strategies for daily activities, teaching individuals how to simplify tasks, use assistive devices, and maintain autonomy in self-care.

7. Personalized and Integrated Care

Given the variability in PD symptoms and progression, modern management increasingly emphasizes personalized medicine: tailoring treatment to each individual’s genetic, biological, and lifestyle profile. Wearable sensors, smartphone-based motor assessments, and telehealth tools now allow for continuous monitoring of tremor, gait, and medication response. This data-driven approach helps clinicians fine-tune therapy in real time, empowering patients to take a more active role in managing their health.

For continuing education participants, especially older adults, understanding these evolving therapeutic strategies can reduce fear, increase hope, and foster proactive engagement in self-care. Whether through medication, surgery, or lifestyle change, PD treatment exemplifies how medical science, technology, and personal resilience converge to sustain brain fitness and dignity throughout aging.

Section IV: Lifestyle Strategies, Research Advances, and Quality-of-Life Approaches for Parkinson’s Disease

(Fisher et al., 2008), (Cotman et al., 2007), (Shulman et al., 2013), (Li et al., 2012), (Cruise et al., 2011), (Gao et al., 2012), (Kiecolt-Glaser et al., 2013), (Maraki et al., 2019), (Pal et al., 2022), (Pfeiffer, 2016), (Kehagia et al., 2010), (Lampit et al., 2014), (Fratiglioni et al., 2004), (Pickut et al., 2013), (Videnovic et al., 2014), (Cameron et al., 2014), (Fratiglioni et al., 2004), (Espay et al., 2017), (Arora et al., 2015)

While pharmacological and surgical treatments are central to managing Parkinson’s disease (PD), everyday strategies, lifestyle modifications, and emerging research play an equally important role in improving quality of life and promoting brain health. For older adults, who are disproportionately affected by PD, education on practical interventions can empower autonomy, reduce symptom burden, and foster social and cognitive engagement.

1. Physical Activity and Exercise for Brain Fitness

Exercise is one of the most effective lifestyle interventions for individuals with PD, demonstrating benefits across motor, cognitive, and emotional domains. Aerobic exercise, such as brisk walking, cycling, or swimming, improves cardiovascular health, gait, and balance while promoting neuroplasticity. Studies show that aerobic activity increases brain-derived neurotrophic factor (BDNF) levels, which support neuronal survival, synaptic plasticity, and dopamine receptor function.

Resistance training complements aerobic activity by strengthening muscles, improving posture, and reducing fall risk. Balance-focused exercises, including tai chi and yoga, enhance proprioception, coordination, and flexibility, which is critical for preventing injuries. A 12-month study of tai chi in older adults with PD reported significant improvements in functional mobility and reduced falls compared with conventional exercise.

Importantly, exercise interventions have psychological benefits as well. Participants frequently report improved mood, reduced apathy, and enhanced quality of life. Group classes also provide social engagement, helping to mitigate isolation and depression, which are common challenges in older adults with PD.

2. Nutrition and Cognitive Health

Nutrition plays a supporting role in brain health and may influence PD progression. Diets rich in antioxidants, such as vitamins C and E, carotenoids, and polyphenols, can help neutralize reactive oxygen species implicated in dopaminergic neuron degeneration. Omega-3 fatty acids, found in fatty fish, flaxseed, and walnuts, may reduce neuroinflammation and support overall brain health.

Emerging research highlights the role of the Mediterranean diet, characterized by high intake of vegetables, fruits, legumes, whole grains, fish, and olive oil, in lowering PD risk and slowing symptom progression. Adequate hydration, fiber intake, and gut-friendly foods such as prebiotics and probiotics may also help manage constipation, a common non-motor symptom of PD, while supporting a healthy gut microbiome, which is increasingly linked to PD pathophysiology.

Maintaining consistent protein intake is another practical consideration. High protein in meals can interfere with levodopa absorption, so timed protein intake, such as consuming most protein in the evening, can enhance daytime motor control. Teaching older adults these subtle dietary adjustments can empower self-management and improve daily function.

3. Cognitive Training and Mental Stimulation

Cognitive decline is common in PD, particularly in executive function, attention, and memory domains. Cognitive training programs: including memory exercises, problem-solving tasks, and computerized brain games, can help strengthen neural networks and delay cognitive deterioration.

Engagement in social and leisure activities, such as reading, puzzles, arts, and volunteering, also supports mental stimulation. Social interaction itself enhances neuroplasticity, reduces stress, and protects against depression, an important consideration for older adults who may face shrinking social networks.

4. Stress Management and Mind-Body Approaches

Chronic stress exacerbates PD symptoms by increasing cortisol, oxidative stress, and neuroinflammation. Mind-body interventions, including mindfulness meditation, yoga, and relaxation techniques, have demonstrated benefits for emotional well-being, sleep quality, and even motor symptoms. Breathing exercises and guided imagery can help manage anxiety and depression, supporting both mental and physical resilience.

Integrating sleep hygiene strategies is equally important. Poor sleep worsens motor function, cognitive performance, and mood. Techniques include maintaining consistent sleep schedules, limiting evening stimulants, and optimizing bedroom environment.

5. Caregiver Support and Social Networks

For many older adults with PD, maintaining independence requires the active support of caregivers, family, and community networks. Caregiver education programs improve knowledge of PD symptoms, medication management, fall prevention, and communication strategies. Support groups provide emotional support, reduce isolation, and allow participants to share practical solutions, which is beneficial for both patients and caregivers.

Social engagement also has neuroprotective effects. Regular interaction can stimulate cognitive reserve, reinforce motor skills through group activities, and enhance emotional resilience. Encouraging older adults to remain socially connected through clubs, faith communities, or volunteer work, can be as important as pharmacological interventions.

6. Cutting-Edge Research and Future Directions

Recent scientific advances offer hope for slowing or even modifying PD progression. In addition to gene therapy, cell-based interventions, and immunotherapies targeting alpha-synuclein discussed earlier, precision medicine approaches are emerging. Researchers are exploring biomarkers from blood, cerebrospinal fluid, and imaging studies to personalize therapy, identify preclinical disease, and predict treatment response.

Digital health technologies, including wearable sensors, smartphone apps, and telemedicine, are transforming symptom monitoring, medication adherence, and remote therapy delivery. These tools enable older adults to actively engage in disease management, receive timely interventions, and maintain independence.

7. Integrating Lifestyle, Medical Care, and Brain Fitness

The ultimate approach to PD is multimodal and involves integrating medical treatment, exercise, nutrition, cognitive training, stress management, and social support. For older adults, this holistic model fosters brain fitness, resilience, and improved quality of life. Educators and healthcare providers can empower participants by teaching practical strategies: simple exercise routines, meal planning tips, cognitive exercises, relaxation techniques, and social engagement activities.

By combining scientific understanding of PD with actionable lifestyle interventions, continuing education programs can help older adults maintain autonomy, preserve function, and approach each day with confidence and purpose. Knowledge of brain plasticity, neuroprotection, and compensatory strategies reinforces the message that, while PD is challenging, meaningful improvements in health and well-being are achievable.

Conclusion

Parkinson’s disease is a multifaceted disorder that touches nearly every aspect of a person’s life, from movement and cognition to mood and daily routines. Understanding early signs, recognizing the intricate brain changes, and learning about both established and emerging therapies can empower individuals to take an active role in managing the condition. Importantly, lifestyle interventions, including exercise, nutrition, cognitive training, stress management, and social engagement, complement medical treatments and foster brain fitness, resilience, and overall well-being.

For older adults and caregivers, knowledge is power. By integrating evidence-based strategies, maintaining social connections, and embracing the potential for neuroplasticity, individuals can preserve independence and quality of life. The story of PD is not only one of challenge but also of hope, adaptation, and the human capacity for resilience. Education, awareness, and proactive engagement provide the tools to navigate PD with confidence, optimism, and purpose.

References

American Parkinson Disease Association. (2025, May 14). New Parkinson’s disease treatments in the clinical trial pipeline. https://www.apdaparkinson.org/article/new-pd-treatments-clinical-trial-pipeline/

Arora, S., Venkataraman, V., Zhan, A., Donohue, S., Biglan, K. M., Dorsey, E. R., & Little, M. A. (2015). Detecting and monitoring the symptoms of Parkinson’s disease using smartphones: A pilot study. Parkinsonism & Related Disorders, 21(6), 650–653. https://doi.org/10.1016/j.parkreldis.2015.03.005

Barker, R. A., Parmar, M., Studer, L., & Takahashi, J. (2017). Human trials of stem cell-derived dopamine neurons for Parkinson’s disease: Dawn of a new era. Cell Stem Cell, 21(5), 569–573. https://doi.org/10.1016/j.stem.2017.10.006

Benabid, A. L., Chabardes, S., Mitrofanis, J., & Pollak, P. (2009). Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. The Lancet Neurology, 8(1), 67–81. https://doi.org/10.1016/S1474-4422(08)70291-6

Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211. https://doi.org/10.1016/S0197-4580(02)00065-9

Carbon, M., & Eidelberg, D. (2006). Functional imaging of sequence learning in Parkinson’s disease. Journal of Neurology, 253(S7), VII21–VII28. https://doi.org/10.1007/s00415-006-7006-3

Cameron, M. H., Ellis, T., Breuer, P., & Hentz, J. (2014). Parkinson disease rehabilitation: A practical guide for physical therapists. PM&R, 6(9 Suppl), S52–S63. https://doi.org/10.1016/j.pmrj.2014.06.008

Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., & Bankiewicz, K. S. (2019). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 92(6), e595–e604. https://doi.org/10.1212/WNL.0000000000006932

Connolly, B. S., & Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: A review. JAMA, 311(16), 1670–1683. https://doi.org/10.1001/jama.2014.3654

Cotman, C. W., Berchtold, N. C., & Christie, L. A. (2007). Exercise builds brain health: Key roles of growth factor cascades and inflammation. Trends in Neurosciences, 30(9), 464–472. https://doi.org/10.1016/j.tins.2007.06.011

Cruise, K. E., Bucks, R. S., Loftus, A. M., Newton, R. U., Pegoraro, R., & Thomas, M. G. (2011). Exercise and Parkinson’s: Benefits for cognition and quality of life. Acta Neurologica Scandinavica, 123(1), 13–19. https://doi.org/10.1111/j.1600-0404.2010.01381.x

DeLong, M. R., & Wichmann, T. (2007). Circuits and circuit disorders of the basal ganglia. Archives of Neurology, 64(1), 20–24. https://doi.org/10.1001/archneur.64.1.20

Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson’s Disease, 8(s1), S3–S8. https://doi.org/10.3233/JPD-181474

Elias, W. J., Lipsman, N., Ondo, W. G., Ghanouni, P., Kim, Y. G., Lee, W., … & Huss, D. (2016). A randomized trial of focused ultrasound thalamotomy for essential tremors. New England Journal of Medicine, 375, 730–739. https://doi.org/10.1056/NEJMoa1600159

Espay, A. J., Lang, A. E., & Bloem, B. R. (2017). Precision medicine for Parkinson’s disease: The next chapter. JAMA Neurology, 74(12), 1365–1366. https://doi.org/10.1001/jamaneurol.2017.1818

Fasano, A., Daniele, A., & Albanese, A. (2012). Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. The Lancet Neurology, 11(5), 429–442. https://doi.org/10.1016/S1474-4422(12)70049-1

Fisher, B. E., Wu, A. D., Salem, G. J., Song, J., Lin, C. H., Yip, J., … & Petzinger, G. M. (2008). The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Archives of Physical Medicine and Rehabilitation, 89(7), 1221–1229. https://doi.org/10.1016/j.apmr.2007.11.049

Fox, S. H., Katzenschlager, R., Lim, S. Y., Barton, B., de Bie, R. M., Seppi, K., & Coelho, M. (2018). International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Movement Disorders, 33(8), 1248–1266. https://doi.org/10.1002/mds.27372

Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2012). Diet and Parkinson’s disease: A review of the evidence. Journal of Parkinson’s Disease, 2(4), 599–608. https://doi.org/10.3233/JPD-2012-12058

Hauser, R. A. (2009). Levodopa: Past, present, and future. European Neurology, 62(1), 1–8. https://doi.org/10.1159/000211753

Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3

Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in Parkinson’s disease. The Lancet Neurology, 9(12), 1200–1213. https://doi.org/10.1016/S1474-4422(10)70212-X

Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., ... & Takahashi, J. (2021). Human iPS cell–derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature, 579(7798), 543–548. https://doi.org/10.1038/s41586-020-2234-1

Li, F., Harmer, P., Fitzgerald, K., Eckstrom, E., Stock, R., Galver, J., … & Batya, S. (2012). Tai chi and postural stability in patients with Parkinson’s disease. New England Journal of Medicine, 366, 511–519. https://doi.org/10.1056/NEJMoa1112916

Lampit, A., Hallock, H., & Valenzuela, M. (2014). Computerized cognitive training in cognitively healthy older adults: A systematic review and meta-analysis of effect modifiers. PLoS Medicine, 11(11), e1001756. https://doi.org/10.1371/journal.pmed.1001756

Maraki, M. I., Yannakoulia, M., Stamelou, M., et al. (2019). Mediterranean diet adherence is related to reduced probability of prodromal Parkinson’s disease. Movement Disorders, 34(8), 1193–1200. https://doi.org/10.1002/mds.27704

Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A. E., ... & Bankiewicz, K. S. (2010). Safety and tolerability of intraputaminal delivery of CERE-120 (AAV2–neurturin) to patients with Parkinson’s disease: An open-label, phase I trial. Lancet Neurology, 9(5), 408–416. https://doi.org/10.1016/S1474-4422(10)70074-4

Michael J. Fox Foundation. (2025, August 7). Advances in Parkinson’s therapies: Five key areas to watch. https://www.michaeljfox.org/news/advances-parkinsons-therapies-five-key-areas-watch

Mortiboys, H., Johansen, K., Aasly, J., Bandmann, O., & Cooper, J. M. (2015). Urso- and tauroursodeoxycholic acid improve mitochondrial function in fibroblasts from patients with Parkinson’s disease. Brain, 138(10), 2974–2986. https://doi.org/10.1093/brain/awv216

Olanow, C. W., Kieburtz, K., & Schapira, A. H. V. (2009). Disease-modifying therapies for Parkinson’s disease. Movement Disorders, 24(S2), S2–S14. https://doi.org/10.1002/mds.22383

Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Meeus, M., Cattaneo, C., ... & Schapira, A. H. V. (2022). Trial of prasinezumab in early-stage Parkinson’s disease. New England Journal of Medicine, 387(5), 421–432. https://doi.org/10.1056/NEJMoa2202863

Pfeiffer, R. F. (2016). Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism & Related Disorders, 22(S1), S66–S70. https://doi.org/10.1016/j.parkreldis.2014.09.018

Pickut, B. A., Van Hees, J., D’hooge, A., et al. (2013). Mindfulness based intervention in Parkinson’s disease leads to structural brain changes on MRI: A randomized controlled trial. Parkinsonism & Related Disorders, 19(11), 1049–1055. https://doi.org/10.1016/j.parkreldis.2013.08.003

Ramig, L. O., Sapir, S., Countryman, S., Pawlas, A., O’Brien, C., Hoehn, M., & Thompson, L. (2001). Intensive voice treatment (LSVT) for patients with Parkinson’s disease: A 2-year follow-up. Journal of Neurology, Neurosurgery & Psychiatry, 71(4), 493–498. https://doi.org/10.1136/jnnp.71.4.493

Schwab, R. S., England, A. C., & Brin, M. F. (2013). Amantadine in Parkinson’s disease: Clinical experience and pharmacology. Advances in Neurology, 60, 281–285. https://doi.org/10.1016/j.apmr.2007.11.049

Seppi, K., Ray Chaudhuri, K., Coelho, M., et al. (2019). Update on treatments for nonmotor symptoms of Parkinson’s disease—An evidence-based medicine review. Movement Disorders, 34(2), 180–198. https://doi.org/10.1002/mds.27605

Shulman, L. M., Katzel, L. I., Ivey, F. M., et al. (2013). Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurology, 70(2), 183–190. https://doi.org/10.1001/jamaneurol.2013.646

Tanner, C. M., Kamel, F., Ross, G. W., et al. (2011). Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives, 119(6), 866–872. https://doi.org/10.1289/ehp.1002839

Videnovic, A., Lazar, A. S., Barker, R. A., & Overeem, S. (2014). ‘The clocks that time us’—Circadian rhythms in neurodegenerative disorders. Nature Reviews Neurology, 10(12), 683–693. https://doi.org/10.1038/nrneurol.2014.169

Witt, K., Daniels, C., & Volkmann, J. (2013). Factors associated with neuropsychiatric side effects after STN-DBS in Parkinson’s disease. Parkinsonism & Related Disorders, 19(2), 216–222. https://doi.org/10.1016/j.parkreldis.2012.09.007

Page updated

Report abuse